Genentech Updates On FDA Decision Regarding Avastin
Genentech said that the committee’s vote has no effect on the present availability of Avastin for people with advanced HER2-negative breast cancer in the US. The decision on
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.